Should I buy or sell Neurocrine Biosciences stock right now?

23 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Neurocrine Biosciences in the last year. There are currently 6 hold ratings and 17 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" NBIX shares. View NBIX analyst ratings or view top-rated stocks .

What is Neurocrine Biosciences' stock price target for 2024?

23 equities research analysts have issued twelve-month target prices for Neurocrine Biosciences' stock. Their NBIX share price targets range from $100.00 to $216.00. On average, they predict the company's stock price to reach $147.88 in the next twelve months. This suggests a possible upside of 6.4% from the stock's current price. View analysts price targets for NBIX or view top-rated stocks among Wall Street analysts .

How have NBIX shares performed in 2024?

Neurocrine Biosciences' stock was trading at $131.76 at the beginning of 2024. Since then, NBIX stock has increased by 5.5% and is now trading at $139.02. View the best growth stocks for 2024 here .

Are investors shorting Neurocrine Biosciences?

Neurocrine Biosciences saw a decline in short interest in the month of April. As of April 15th, there was short interest totaling 2,020,000 shares, a decline of 16.9% from the March 31st total of 2,430,000 shares. Based on an average daily volume of 875,200 shares, the days-to-cover ratio is presently 2.3 days. View Neurocrine Biosciences' Short Interest .

When is Neurocrine Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 6th 2024. View our NBIX earnings forecast .

How were Neurocrine Biosciences' earnings last quarter?

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) issued its quarterly earnings data on Wednesday, February, 7th. The company reported $1.44 EPS for the quarter, beating analysts' consensus estimates of $1.13 by $0.31. The business earned $515.20 million during the quarter, compared to the consensus estimate of $518.52 million. Neurocrine Biosciences had a net margin of 18.65% and a trailing twelve-month return on equity of 17.45%. The business's revenue was up 25.0% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.88 earnings per share.

What ETFs hold Neurocrine Biosciences' stock?

ETFs with the largest weight of Neurocrine Biosciences (NASDAQ:NBIX) stock in their portfolio include Invesco Biotechnology & Genome ETF (PBE) , iShares Neuroscience and Healthcare ETF (IBRN) , First Trust NYSE Arca Biotechnology Index Fund (FBT) , Janus Henderson Small/Mid Cap Growth Alpha ETF (JSMD) , VanEck Biotech ETF (BBH) , Goldman Sachs Future Health Care Equity ETF (GDOC) , Virtus LifeSci Biotech Products ETF (BBP) and Invesco Bloomberg Pricing Power ETF (DEF) .

What is Kevin C. Gorman's approval rating as Neurocrine Biosciences' CEO?

11 employees have rated Neurocrine Biosciences Chief Executive Officer Kevin C. Gorman on Glassdoor.com . Kevin C. Gorman has an approval rating of 97% among the company's employees. This puts Kevin C. Gorman in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Neurocrine Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Neurocrine Biosciences investors own include NVIDIA (NVDA) , Gilead Sciences (GILD) , Micron Technology (MU) , Alibaba Group (BABA) , Netflix (NFLX) , AbbVie (ABBV) , Walt Disney (DIS) , Tesla (TSLA) , Block (SQ) and Salesforce (CRM) .

Who are Neurocrine Biosciences' major shareholders?

Neurocrine Biosciences' stock is owned by a number of institutional and retail investors. Top institutional investors include Bank of New York Mellon Corp (0.93%), Allspring Global Investments Holdings LLC (0.51%), Allspring Global Investments Holdings LLC (0.51%), BNP Paribas Financial Markets (0.43%), Principal Financial Group Inc. (0.42%) and Russell Investments Group Ltd. (0.35%). Insiders that own company stock include Darin Lippoldt , David W Boyer , Dimitri E Grigoriadis , Eiry Roberts , Eric Benevich , Gary A Lyons , George J Morrow, Ingrid Delaet , Jude Onyia , Julie Cooke , Kevin Charles Gorman , Kyle Gano , Leslie V Norwalk, Malcolm Lloyd-Smith , Matt Abernethy , Neurocrine Biosciences Inc, Richard F Pops , Stephen A Sherwin and William H Rastetter . View institutional ownership trends .

How do I buy shares of Neurocrine Biosciences?

Shares of NBIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:NBIX

Neurocrine Biosciences (NBIX) Stock Price, News & Analysis

→ The new financial threat that could wipe out millions… (From InvestorPlace) (Ad)

Free NBIX Stock Alerts

$139.02

-4.17 (-2.91%)

(As of 05/8/2024 ET)

Compare

Today's Range: $138.15
▼
$143.54
50-Day Range: $130.40
▼
$143.74
52-Week Range: $89.04
▼
$148.37

Volume: 653,593 shs
Average Volume: 845,459 shs
Market Capitalization: $13.99 billion

P/E Ratio: 38.30
Dividend Yield: N/A
Price Target: $147.88

Get Neurocrine Biosciences alerts:

Neurocrine Biosciences MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.74 Rating Score
Upside/Downside: 6.4% Upside
$147.88 Price Target
Short Interest: Healthy
2.01% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -2.61
Upright™ Environmental Score
News Sentiment: 0.45
Based on 46 Articles This Week
Insider Trading: Selling Shares
$24.40 M Sold Last Quarter
Proj. Earnings Growth: 33.68%
From $4.78 to $6.39 Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.61 out of 5 stars

Medical Sector

70th out of 905 stocks

Biological Products, Except Diagnostic Industry

6th out of 154 stocks

2.4

Analyst's Opinion

Consensus Rating
Neurocrine Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.74, and is based on 17 buy ratings, 6 hold ratings, and no sell ratings.
Amount of Analyst Coverage
Neurocrine Biosciences has been the subject of 13 research reports in the past 90 days, demonstrating strong analyst interest in this stock.
Read more about Neurocrine Biosciences' stock forecast and price target.

5.0

Short Interest

Percentage of Shares Shorted
2.01% of the outstanding shares of Neurocrine Biosciences have been sold short.
Short Interest Ratio / Days to Cover
Neurocrine Biosciences has a short interest ratio ("days to cover") of 2.3, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Neurocrine Biosciences has recently decreased by 16.87%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Neurocrine Biosciences does not currently pay a dividend.
Dividend Growth
Neurocrine Biosciences does not have a long track record of dividend growth.

2.9

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Neurocrine Biosciences has received a 24.32% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Valbenazine", "Elagolix", and "Opicapone" products. See details.
Environmental Sustainability
The Environmental Impact score for Neurocrine Biosciences is -2.61.

2.5

News and Social Media Coverage

News Sentiment
Neurocrine Biosciences has a news sentiment score of 0.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 46 news articles for Neurocrine Biosciences this week, compared to 9 articles on an average week.
Search Interest
Only 5 people have searched for NBIX on MarketBeat in the last 30 days. This is a decrease of -17% compared to the previous 30 days.
MarketBeat Follows
13 people have added Neurocrine Biosciences to their MarketBeat watchlist in the last 30 days. This is an increase of 8% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Neurocrine Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $24,399,293.00 in company stock.
Percentage Held by Insiders
Only 4.30% of the stock of Neurocrine Biosciences is held by insiders.
Percentage Held by Institutions
92.59% of the stock of Neurocrine Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.
Read more about Neurocrine Biosciences' insider trading history.

3.1

Earnings and Valuation

Earnings Growth
Earnings for Neurocrine Biosciences are expected to grow by 33.68% in the coming year, from $4.78 to $6.39 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Neurocrine Biosciences is 38.30, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 141.48.
Price to Earnings Ratio vs. Sector
The P/E ratio of Neurocrine Biosciences is 38.30, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 178.55.
Price to Book Value per Share Ratio
Neurocrine Biosciences has a P/B Ratio of 6.12. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.
Read more about Neurocrine Biosciences' valuation and earnings.

See Top Rated MarketRank™ Stocks Here

Ad Behind the Markets

The Weight Loss Pill That Could Disrupt a $32 Billion Industry

A revolutionary new weight loss pill is about to send shockwaves through the plus-size clothing market. Analysts are calling it the "King Kong" of diet drugs after amazing clinical trial results.

Don't miss out on the "next Ozempic" >>>

About Neurocrine Biosciences Stock (NASDAQ:NBIX)

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy in pediatrics and adults; NBI-921352 to treat developmental and epileptic encephalopathy syndrome in pediatrics and adults; NBI-827104 to treat epileptic encephalopathy with continuous spike-and-wave during sleep; NBI-1076986 to treat movement disorders; crinecerfront to treat congenital adrenal hyperplasia in adults and children; EFMODY to treat congenital adrenal hyperplasia and adrenal insufficiency in adults; valbenazine for the adjunctive treatment of schizophrenia; NBI-1065845 for the treatment of inadequate response to treatment in major depressive disorder; luvadaxistat to treat cognitive impairment related to schizophrenia; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; NBI-1117570 for the treatment of symptoms of psychosis and cognition in neurological and neuropsychiatric conditions; and NBI-1117569, NBI-1117567, and NBI-1065890 to treat CNS indications. The company also has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.

NBIX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

NBIX Stock News Headlines

April 18, 2024 | insidertrades.com

Insider Selling: Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Insider Sells 19,818 Shares of Stock

April 16, 2024 | insidertrades.com

The 5 Stocks Most Sold By Insiders This Year (NBIX)

May 8, 2024 | InvestorPlace (Ad)

The new financial threat that could wipe out millions…

During the Internet boom, companies like Pets.com were supposed to be promising investments riding the wave of a new tech boom. But then they were gone within a blink of an eye. One of the most successful investors in history just stepped forward to say the same thing is about to happen to AI stocks.

May 8, 2024 | prnewswire.com

Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1117567 in Healthy Adults

May 7, 2024 | prnewswire.com

Neurocrine Biosciences to Present at the BofA Securities 2024 Health Care Conference

May 7, 2024 | prnewswire.com

Neurocrine Biosciences to Present Phase 3 Baseline Characteristics Data from the CAHtalyst™ Program of Crinecerfont in CAH, and Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH Studies at ECE 2024

May 7, 2024 | americanbankingnews.com

Citigroup Raises Neurocrine Biosciences (NASDAQ:NBIX) Price Target to $150.00

May 6, 2024 | prnewswire.com

Neurocrine Biosciences Supports Tardive Dyskinesia Awareness Week by Advocating for Routine Screening and Monitoring

May 8, 2024 | InvestorPlace (Ad)

The new financial threat that could wipe out millions…